nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—ABCB1—adrenal gland cancer	0.934	1	CbGaD
Nefazodone—SLC6A2—sympathetic nervous system—adrenal gland cancer	0.00848	0.235	CbGeAlD
Nefazodone—HTR2A—sympathetic nervous system—adrenal gland cancer	0.0051	0.141	CbGeAlD
Nefazodone—HTR2A—vein—adrenal gland cancer	0.00477	0.132	CbGeAlD
Nefazodone—HTR2A—urine—adrenal gland cancer	0.00279	0.0775	CbGeAlD
Nefazodone—CYP3A4—urine—adrenal gland cancer	0.00259	0.0717	CbGeAlD
Nefazodone—CYP2D6—urine—adrenal gland cancer	0.00254	0.0706	CbGeAlD
Nefazodone—SLC6A2—gonad—adrenal gland cancer	0.00102	0.0283	CbGeAlD
Nefazodone—Domperidone—ABCB1—adrenal gland cancer	0.000908	0.241	CrCbGaD
Nefazodone—HTR1A—adrenal gland—adrenal gland cancer	0.000896	0.0249	CbGeAlD
Nefazodone—SLC6A2—adrenal gland—adrenal gland cancer	0.000889	0.0247	CbGeAlD
Nefazodone—ADRA1A—adrenal gland—adrenal gland cancer	0.000826	0.0229	CbGeAlD
Nefazodone—ADRA2A—gonad—adrenal gland cancer	0.000721	0.02	CbGeAlD
Nefazodone—ADRA2A—cardiac atrium—adrenal gland cancer	0.00072	0.02	CbGeAlD
Nefazodone—ADRA2A—pituitary gland—adrenal gland cancer	0.000703	0.0195	CbGeAlD
Nefazodone—Aripiprazole—ABCB1—adrenal gland cancer	0.000701	0.186	CrCbGaD
Nefazodone—Trazodone—ABCB1—adrenal gland cancer	0.000698	0.185	CrCbGaD
Nefazodone—ADRA2A—adrenal gland—adrenal gland cancer	0.000628	0.0174	CbGeAlD
Nefazodone—HTR2A—gonad—adrenal gland cancer	0.000613	0.017	CbGeAlD
Nefazodone—HTR2A—pituitary gland—adrenal gland cancer	0.000598	0.0166	CbGeAlD
Nefazodone—Fluphenazine—ABCB1—adrenal gland cancer	0.000565	0.15	CrCbGaD
Nefazodone—HTR2A—adrenal gland—adrenal gland cancer	0.000534	0.0148	CbGeAlD
Nefazodone—ABCB1—adrenal cortex—adrenal gland cancer	0.000485	0.0135	CbGeAlD
Nefazodone—Trifluoperazine—ABCB1—adrenal gland cancer	0.000452	0.12	CrCbGaD
Nefazodone—Quetiapine—ABCB1—adrenal gland cancer	0.000438	0.116	CrCbGaD
Nefazodone—ABCB1—gonad—adrenal gland cancer	0.000402	0.0111	CbGeAlD
Nefazodone—ABCB1—pituitary gland—adrenal gland cancer	0.000392	0.0109	CbGeAlD
Nefazodone—ABCB1—adrenal gland—adrenal gland cancer	0.00035	0.00971	CbGeAlD
Nefazodone—HTR2A—GPCR ligand binding—GNAS—adrenal gland cancer	4.39e-05	0.00168	CbGpPWpGaD
Nefazodone—SLC6A4—Circadian rythm related genes—TP53—adrenal gland cancer	4.36e-05	0.00167	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—GNRH1—adrenal gland cancer	4.35e-05	0.00166	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—GNRH1—adrenal gland cancer	4.34e-05	0.00166	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ZNRF3—adrenal gland cancer	4.33e-05	0.00166	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ZNRF3—adrenal gland cancer	4.31e-05	0.00165	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	4.3e-05	0.00164	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—GNAS—adrenal gland cancer	4.3e-05	0.00164	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—GNRHR—adrenal gland cancer	4.28e-05	0.00164	CbGpPWpGaD
Nefazodone—ADRA1B—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	4.28e-05	0.00163	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—TSHR—adrenal gland cancer	4.27e-05	0.00163	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—TSHR—adrenal gland cancer	4.26e-05	0.00163	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—GNRH1—adrenal gland cancer	4.25e-05	0.00162	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—ABCB1—adrenal gland cancer	4.22e-05	0.00161	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—GNRHR—adrenal gland cancer	4.19e-05	0.0016	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—TSHR—adrenal gland cancer	4.17e-05	0.00159	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—SDHD—adrenal gland cancer	4.16e-05	0.00159	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—RRM1—adrenal gland cancer	4.16e-05	0.00159	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ZNRF3—adrenal gland cancer	4.13e-05	0.00158	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—GNAS—adrenal gland cancer	3.99e-05	0.00152	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SH3KBP1—adrenal gland cancer	3.98e-05	0.00152	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—GNRH1—adrenal gland cancer	3.95e-05	0.00151	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—adrenal gland cancer	3.93e-05	0.0015	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SH3KBP1—adrenal gland cancer	3.9e-05	0.00149	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—GNRHR—adrenal gland cancer	3.9e-05	0.00149	CbGpPWpGaD
Nefazodone—HTR2A—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	3.88e-05	0.00148	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—TSHR—adrenal gland cancer	3.88e-05	0.00148	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—TSHR—adrenal gland cancer	3.87e-05	0.00148	CbGpPWpGaD
Nefazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	3.8e-05	0.00145	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—TSHR—adrenal gland cancer	3.79e-05	0.00145	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ZNRF3—adrenal gland cancer	3.74e-05	0.00143	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—CDC42—adrenal gland cancer	3.74e-05	0.00143	CbGpPWpGaD
Nefazodone—CYP2D6—Biological oxidations—POMC—adrenal gland cancer	3.71e-05	0.00142	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ZNRF3—adrenal gland cancer	3.67e-05	0.0014	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SH3KBP1—adrenal gland cancer	3.62e-05	0.00138	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—IGF2—adrenal gland cancer	3.6e-05	0.00138	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—GNAS—adrenal gland cancer	3.57e-05	0.00136	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	3.53e-05	0.00135	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—SDHB—adrenal gland cancer	3.52e-05	0.00135	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—TSHR—adrenal gland cancer	3.52e-05	0.00135	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—POMC—adrenal gland cancer	3.42e-05	0.00131	CbGpPWpGaD
Nefazodone—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	3.41e-05	0.0013	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ZNRF3—adrenal gland cancer	3.41e-05	0.0013	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—POMC—adrenal gland cancer	3.4e-05	0.0013	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—SDHB—adrenal gland cancer	3.32e-05	0.00127	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—RRM1—adrenal gland cancer	3.28e-05	0.00125	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—SDHD—adrenal gland cancer	3.28e-05	0.00125	CbGpPWpGaD
Nefazodone—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	3.27e-05	0.00125	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—POMC—adrenal gland cancer	3.26e-05	0.00124	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—PRKACA—adrenal gland cancer	3.22e-05	0.00123	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—PRKACA—adrenal gland cancer	3.2e-05	0.00122	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—MED12—adrenal gland cancer	3.1e-05	0.00119	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—PRKACA—adrenal gland cancer	3.06e-05	0.00117	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—SDHD—adrenal gland cancer	3.01e-05	0.00115	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—RRM1—adrenal gland cancer	3.01e-05	0.00115	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—CDC42—adrenal gland cancer	3e-05	0.00115	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—CDC42—adrenal gland cancer	2.99e-05	0.00114	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—GNRH1—adrenal gland cancer	2.97e-05	0.00113	CbGpPWpGaD
Nefazodone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	2.96e-05	0.00113	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—GNRH1—adrenal gland cancer	2.95e-05	0.00113	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—POMC—adrenal gland cancer	2.95e-05	0.00113	CbGpPWpGaD
Nefazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	2.9e-05	0.00111	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—POMC—adrenal gland cancer	2.89e-05	0.00111	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—adrenal gland cancer	2.89e-05	0.0011	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—GNAS—adrenal gland cancer	2.87e-05	0.0011	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—CDC42—adrenal gland cancer	2.86e-05	0.00109	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—GNAS—adrenal gland cancer	2.86e-05	0.00109	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—GNRH1—adrenal gland cancer	2.83e-05	0.00108	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—PRKACA—adrenal gland cancer	2.78e-05	0.00106	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—GNAS—adrenal gland cancer	2.73e-05	0.00104	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—CDC42—adrenal gland cancer	2.73e-05	0.00104	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—PRKACA—adrenal gland cancer	2.72e-05	0.00104	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SPRY2—adrenal gland cancer	2.72e-05	0.00104	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—CDC42—adrenal gland cancer	2.71e-05	0.00104	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SPRY2—adrenal gland cancer	2.7e-05	0.00103	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—POMC—adrenal gland cancer	2.69e-05	0.00103	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TSHR—adrenal gland cancer	2.65e-05	0.00101	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—PRKACA—adrenal gland cancer	2.64e-05	0.00101	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TSHR—adrenal gland cancer	2.63e-05	0.00101	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—GNAS—adrenal gland cancer	2.61e-05	0.000996	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—CDC42—adrenal gland cancer	2.6e-05	0.000992	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—CDC42—adrenal gland cancer	2.6e-05	0.000991	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—GNAS—adrenal gland cancer	2.59e-05	0.000991	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SPRY2—adrenal gland cancer	2.59e-05	0.000988	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—adrenal gland cancer	2.59e-05	0.000988	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—GNRH1—adrenal gland cancer	2.57e-05	0.00098	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—CDC42—adrenal gland cancer	2.54e-05	0.000971	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—PRKACA—adrenal gland cancer	2.53e-05	0.000966	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TSHR—adrenal gland cancer	2.52e-05	0.000963	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—GNRH1—adrenal gland cancer	2.51e-05	0.00096	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MEN1—adrenal gland cancer	2.49e-05	0.000951	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—GNAS—adrenal gland cancer	2.48e-05	0.000948	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—GNAS—adrenal gland cancer	2.48e-05	0.000947	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MEN1—adrenal gland cancer	2.48e-05	0.000946	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—MED12—adrenal gland cancer	2.45e-05	0.000935	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—GNAS—adrenal gland cancer	2.43e-05	0.000927	CbGpPWpGaD
Nefazodone—CYP3A4—Biological oxidations—POMC—adrenal gland cancer	2.43e-05	0.000927	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MEN1—adrenal gland cancer	2.37e-05	0.000905	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—CDC42—adrenal gland cancer	2.36e-05	0.000902	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—CDC42—adrenal gland cancer	2.36e-05	0.0009	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SPRY2—adrenal gland cancer	2.35e-05	0.000896	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—GNRH1—adrenal gland cancer	2.33e-05	0.000892	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—CDC42—adrenal gland cancer	2.31e-05	0.000881	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SPRY2—adrenal gland cancer	2.3e-05	0.000878	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TSHR—adrenal gland cancer	2.29e-05	0.000874	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—RRM1—adrenal gland cancer	2.27e-05	0.000867	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—SDHD—adrenal gland cancer	2.27e-05	0.000867	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PRKACA—adrenal gland cancer	2.26e-05	0.000865	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—GNAS—adrenal gland cancer	2.26e-05	0.000862	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—GNAS—adrenal gland cancer	2.25e-05	0.00086	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—MED12—adrenal gland cancer	2.24e-05	0.000857	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TSHR—adrenal gland cancer	2.24e-05	0.000855	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—GNAS—adrenal gland cancer	2.2e-05	0.000842	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SDHB—adrenal gland cancer	2.17e-05	0.000829	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MEN1—adrenal gland cancer	2.15e-05	0.000821	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—CDC42—adrenal gland cancer	2.14e-05	0.000819	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—RRM1—adrenal gland cancer	2.14e-05	0.000817	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—SDHD—adrenal gland cancer	2.14e-05	0.000817	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	2.14e-05	0.000816	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SPRY2—adrenal gland cancer	2.14e-05	0.000816	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MEN1—adrenal gland cancer	2.11e-05	0.000804	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TSHR—adrenal gland cancer	2.08e-05	0.000795	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	2.05e-05	0.000783	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—GNAS—adrenal gland cancer	2.05e-05	0.000783	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MEN1—adrenal gland cancer	1.96e-05	0.000747	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—POMC—adrenal gland cancer	1.93e-05	0.000738	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—POMC—adrenal gland cancer	1.92e-05	0.000734	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PRKACA—adrenal gland cancer	1.9e-05	0.000726	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PRKACA—adrenal gland cancer	1.89e-05	0.000722	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—POMC—adrenal gland cancer	1.84e-05	0.000703	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—GNAS—adrenal gland cancer	1.83e-05	0.000701	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PRKACA—adrenal gland cancer	1.81e-05	0.000691	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—ABCB1—adrenal gland cancer	1.8e-05	0.000688	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PRKACA—adrenal gland cancer	1.79e-05	0.000682	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—POMC—adrenal gland cancer	1.76e-05	0.00067	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—POMC—adrenal gland cancer	1.75e-05	0.000667	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	1.72e-05	0.000657	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—MED12—adrenal gland cancer	1.69e-05	0.000647	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—POMC—adrenal gland cancer	1.67e-05	0.000638	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—POMC—adrenal gland cancer	1.67e-05	0.000638	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PRKACA—adrenal gland cancer	1.64e-05	0.000627	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PRKACA—adrenal gland cancer	1.64e-05	0.000625	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—POMC—adrenal gland cancer	1.63e-05	0.000624	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CDC42—adrenal gland cancer	1.61e-05	0.000616	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PRKACA—adrenal gland cancer	1.61e-05	0.000614	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CDC42—adrenal gland cancer	1.6e-05	0.000612	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—MED12—adrenal gland cancer	1.6e-05	0.000609	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IGF2—adrenal gland cancer	1.55e-05	0.000593	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IGF2—adrenal gland cancer	1.55e-05	0.00059	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—GNAS—adrenal gland cancer	1.54e-05	0.000588	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CDC42—adrenal gland cancer	1.53e-05	0.000586	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—GNAS—adrenal gland cancer	1.53e-05	0.000585	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—POMC—adrenal gland cancer	1.52e-05	0.00058	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—POMC—adrenal gland cancer	1.52e-05	0.000579	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IGF1R—adrenal gland cancer	1.5e-05	0.000574	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IGF1R—adrenal gland cancer	1.49e-05	0.000571	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PRKACA—adrenal gland cancer	1.49e-05	0.00057	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—POMC—adrenal gland cancer	1.48e-05	0.000567	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IGF2—adrenal gland cancer	1.48e-05	0.000565	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—GNAS—adrenal gland cancer	1.47e-05	0.00056	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GNAS—adrenal gland cancer	1.45e-05	0.000553	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IGF1R—adrenal gland cancer	1.43e-05	0.000546	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—ABCB1—adrenal gland cancer	1.42e-05	0.000543	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—RRM1—adrenal gland cancer	1.4e-05	0.000534	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SDHD—adrenal gland cancer	1.4e-05	0.000534	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CDC42—adrenal gland cancer	1.39e-05	0.000532	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—POMC—adrenal gland cancer	1.38e-05	0.000527	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CDC42—adrenal gland cancer	1.36e-05	0.000521	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IGF2—adrenal gland cancer	1.34e-05	0.000513	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—GNAS—adrenal gland cancer	1.33e-05	0.000508	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GNAS—adrenal gland cancer	1.33e-05	0.000507	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IGF2—adrenal gland cancer	1.31e-05	0.000502	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—GNAS—adrenal gland cancer	1.3e-05	0.000498	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ABCB1—adrenal gland cancer	1.3e-05	0.000497	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IGF1R—adrenal gland cancer	1.3e-05	0.000496	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TERT—adrenal gland cancer	1.29e-05	0.000494	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TERT—adrenal gland cancer	1.29e-05	0.000491	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IGF1R—adrenal gland cancer	1.27e-05	0.000485	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CDC42—adrenal gland cancer	1.27e-05	0.000484	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—POMC—adrenal gland cancer	1.24e-05	0.000472	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PRKACA—adrenal gland cancer	1.23e-05	0.000472	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TERT—adrenal gland cancer	1.23e-05	0.00047	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF2—adrenal gland cancer	1.22e-05	0.000466	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—GNAS—adrenal gland cancer	1.21e-05	0.000462	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF1R—adrenal gland cancer	1.18e-05	0.000451	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PRKACA—adrenal gland cancer	1.16e-05	0.000444	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—TP53—adrenal gland cancer	1.14e-05	0.000436	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—BAD—adrenal gland cancer	1.12e-05	0.00043	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—BAD—adrenal gland cancer	1.12e-05	0.000427	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TERT—adrenal gland cancer	1.12e-05	0.000427	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TERT—adrenal gland cancer	1.09e-05	0.000418	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—BAD—adrenal gland cancer	1.07e-05	0.000409	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MED12—adrenal gland cancer	1.04e-05	0.000398	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—POMC—adrenal gland cancer	1.04e-05	0.000396	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—POMC—adrenal gland cancer	1.03e-05	0.000394	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—BRAF—adrenal gland cancer	1.02e-05	0.000391	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—BRAF—adrenal gland cancer	1.02e-05	0.000389	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TERT—adrenal gland cancer	1.02e-05	0.000388	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GNAS—adrenal gland cancer	1e-05	0.000382	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—EGFR—adrenal gland cancer	9.92e-06	0.000379	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—POMC—adrenal gland cancer	9.87e-06	0.000377	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—EGFR—adrenal gland cancer	9.87e-06	0.000377	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTGS2—adrenal gland cancer	9.85e-06	0.000376	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—BRAF—adrenal gland cancer	9.75e-06	0.000372	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—POMC—adrenal gland cancer	9.75e-06	0.000372	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—BAD—adrenal gland cancer	9.72e-06	0.000371	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—BAD—adrenal gland cancer	9.51e-06	0.000363	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—EGFR—adrenal gland cancer	9.45e-06	0.000361	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GNAS—adrenal gland cancer	9.43e-06	0.00036	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ABCB1—adrenal gland cancer	9.25e-06	0.000354	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—POMC—adrenal gland cancer	8.96e-06	0.000342	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—POMC—adrenal gland cancer	8.93e-06	0.000341	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—BRAF—adrenal gland cancer	8.84e-06	0.000338	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—BAD—adrenal gland cancer	8.84e-06	0.000338	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—POMC—adrenal gland cancer	8.77e-06	0.000335	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—BRAF—adrenal gland cancer	8.66e-06	0.000331	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—EGFR—adrenal gland cancer	8.57e-06	0.000327	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—EGFR—adrenal gland cancer	8.39e-06	0.000321	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—POMC—adrenal gland cancer	8.15e-06	0.000311	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—BRAF—adrenal gland cancer	8.05e-06	0.000307	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—EGFR—adrenal gland cancer	7.8e-06	0.000298	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—adrenal gland cancer	7.77e-06	0.000297	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	7.61e-06	0.000291	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CTNNB1—adrenal gland cancer	7.4e-06	0.000283	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CTNNB1—adrenal gland cancer	7.36e-06	0.000281	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—adrenal gland cancer	7.12e-06	0.000272	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CTNNB1—adrenal gland cancer	7.05e-06	0.000269	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—POMC—adrenal gland cancer	6.74e-06	0.000257	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CTNNB1—adrenal gland cancer	6.39e-06	0.000244	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—POMC—adrenal gland cancer	6.35e-06	0.000243	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CTNNB1—adrenal gland cancer	6.26e-06	0.000239	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GNAS—adrenal gland cancer	6.17e-06	0.000236	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	6.05e-06	0.000231	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EGFR—adrenal gland cancer	5.86e-06	0.000224	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EGFR—adrenal gland cancer	5.83e-06	0.000223	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CTNNB1—adrenal gland cancer	5.82e-06	0.000222	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EGFR—adrenal gland cancer	5.58e-06	0.000213	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—adrenal gland cancer	5.38e-06	0.000205	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—adrenal gland cancer	5.07e-06	0.000193	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EGFR—adrenal gland cancer	5.06e-06	0.000193	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EGFR—adrenal gland cancer	4.96e-06	0.000189	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—adrenal gland cancer	4.92e-06	0.000188	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—adrenal gland cancer	4.9e-06	0.000187	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—adrenal gland cancer	4.69e-06	0.000179	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EGFR—adrenal gland cancer	4.61e-06	0.000176	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—adrenal gland cancer	4.25e-06	0.000162	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—adrenal gland cancer	4.16e-06	0.000159	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—POMC—adrenal gland cancer	4.15e-06	0.000159	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—adrenal gland cancer	3.87e-06	0.000148	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	3.31e-06	0.000126	CbGpPWpGaD
